MIRA: Total Utang marang Modal MIRA Pharmaceuticals

MIRA Pharmaceuticals - logo grafis emiten MIRA

MIRA Pharmaceuticals (MIRA) develops treatments for depression and pain, with future profits relying on the sale of patented cannabinoids through insurance companies. Market price action shows that the total debt-to-equity ratio is 0.00. High barriers to entry in this niche are ensured by strict FDA and DEA oversight, as well as exclusive rights to chemical formulas.

MIRA Pharmaceuticals Inc. (MIRA): Rasio Kabeh Utang marang Dana Pribadi saka 21.02.2024 nganti 31.10.2026

Rincian metrik lan analitis perusahaan MIRA Pharmaceuticals, Inc. (MIRA)

- rega lan prakiraan konsensus rega:
Bagan rega MIRA Pharmaceuticals Inc.|MIRA - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar MIRA Pharmaceuticals|MIRA - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham MIRA Pharmaceuticals|MIRA - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku mirapharmaceuticals.com|MIRA - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Utang marang Ekuitas MIRA Pharmaceuticals|MIRA - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas MIRA Pharmaceuticals Inc.|MIRA - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku MIRA Pharmaceuticals|MIRA - Kewajiban jangka dawa|Utang jangka cendhak perusahaan MIRA Pharmaceuticals|Likuiditas cepet mirapharmaceuticals.com
- data bathi resik lan rasio valuasi:
MIRA - Bathi pungkasan
Pambiji fundamental perusahaan:MIRA Pharmaceuticals, MIRA
Barang utama MIRA Pharma

This ratio determines the financing structure by comparing total liabilities to net assets to assess the business's degree of dependence on debt capital. By analyzing the proportion of total debt to equity, an investor can understand how sustainably MIRA Pharmaceuticals (MIRA) finances the development of proprietary cannabinoids amid stringent regulatory oversight from the FDA and DEA, which limits the entry of new competitors into the niche.

Karo sapa MIRA Pharmaceuticals saingan

Utang marang Ekuitas Indivior|Rasio Utang marang Ekuitas COLL (Collegium Pharma)|Total Utang marang Modal CRON|Total Utang marang Modal Canopy Growth Corp. (CGC)|Utang marang Ekuitas High Tide Inc. HITI|Rasio Kabeh Utang marang Dana Pribadi ACB|Achieve Life Sciences, Inc. - Total Utang marang Modal|Skye Bioscience Inc. (SKYE) - Rasio Total Utang marang Ekuitas|Anebulo (ANEB) - Utang marang Ekuitas|Utang marang Modal InterCure (INCR)|Rasio Total Utang marang Ekuitas NTRB|NSRX: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal IGC|FLGC: Utang Agregat marang Ekuitas|Total Utang marang Modal IMCC (IM Cannabis)|Total Utang marang Modal Adial Pharmaceuticals Inc. ADIL|ARTL - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ENSC (Ensysce Biosciences)|titanpharm.com (TTNP) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Greenlane Holdings, Inc.|Utang marang Ekuitas InMed Pharma|Rasio Total Utang marang Ekuitas Akanda Inc (AKAN)|Total Utang marang Modal ENVB|Koefisien Total Utang marang Modal brightgreen.us|Utang marang Ekuitas Hempacco Co., Inc. HPCO